AFMD — Affimed N.V.

Summary of Affimed's Q3 2024 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Ended Q3 2024 with €24.1 million in cash and equivalents, down from €72 million at the end of 2023.
• Net Cash Used: €11.1 million for Q3 2024, a decrease from €18.3 million in Q3 2023.
• Total Revenue: €0.2 million for Q3 2024, significantly down from €2.0 million in the same quarter last year.
• R&D Expenses: €10.1 million in Q3 2024, down from €21.5 million in Q3 2023.
• Net Loss: €15.1 million (or €0.94 per share) for Q3 2024, compared to a net loss of €24.4 million (or €1.63 per share) in Q3 2023.

2. Strategic Updates and Business Highlights

• Clinical Progress:
  • AFM24 and AFM28 are advancing well, with promising data expected to be presented at the ASH 2024 conference.
  • AFM24 is fully enrolled in trials for non-small cell lung cancer (NSCLC), showing a disease control rate of 71% in the wild-type cohort.
  • The LuminICE study for Acimtamig in Hodgkin lymphoma is also progressing, with data to be presented at ASH 2024.
• Leadership Transition: Shawn Leland, the new CEO, emphasized the company's commitment to advancing innovative therapies and improving financial health.
• Partnership Strategy: The company is broadening its approach to potential collaborations, seeking diverse partnerships to enhance capital without diluting equity.

3. Forward Guidance and Outlook

• Cash Runway: The current cash position is expected to fund operations into Q4 2025, aided by anticipated proceeds from the ATM program and the sale of AbCheck.
• Clinical Data: Significant updates on AFM24 and AFM28 are expected in December 2024, with further data anticipated in the first half of 2025, potentially leading to discussions with the FDA regarding registration paths.

4. Bad News, Challenges, or Points of Concern

• Declining Revenue: The substantial drop in total revenue and cash reserves raises concerns about financial sustainability and operational capacity.
• Clinical Trial Risks: The reliance on upcoming clinical data for both AFM24 and AFM28 poses risks; any unfavorable results could impact future funding and partnerships.
• Market Environment: The challenging market conditions and competition in the biopharmaceutical sector could hinder partnership opportunities and funding.

5. Notable Q&A Insights

• Durability of Responses: Questions regarding the durability of responses for AFM28 indicated that while some patients are still being treated, follow-up periods may be too short for definitive conclusions.
• Partnership Discussions: The company is exploring various types of partnerships, including regional deals, to secure non-dilutive capital.
• Development Strategy: For AFM24, the focus is on confirming response rates and determining the path to potential registration trials, with a preference for combinations that enhance efficacy.
• Accelerated Approval Path: Discussions on AFM28 indicated a potential strategy for accelerated approval based on single-arm studies in later lines of treatment, contingent on demonstrating robust efficacy and safety profiles.

This summary encapsulates the key financial metrics, strategic initiatives, and insights from the Q&A, providing a balanced view of Affimed's current standing and future outlook.